S&P 500   2,968.44 (-0.06%)
DOW   26,809.34 (-0.03%)
QQQ   191.39 (+0.15%)
AAPL   236.24 (+0.01%)
FB   183.50 (-0.37%)
MSFT   139.89 (+0.15%)
GOOGL   1,220.67 (+0.41%)
AMZN   1,739.59 (+0.44%)
CGC   18.75 (-3.50%)
NVDA   186.48 (+0.26%)
MU   44.87 (-0.51%)
BABA   171.60 (-0.77%)
GE   8.74 (-0.68%)
TSLA   257.17 (+3.74%)
AMD   30.49 (+2.49%)
T   37.46 (-0.32%)
PRI   121.49 (-0.16%)
NFLX   286.50 (+1.26%)
BAC   29.06 (+0.52%)
GILD   64.48 (+0.75%)
DIS   129.77 (-0.19%)
S&P 500   2,968.44 (-0.06%)
DOW   26,809.34 (-0.03%)
QQQ   191.39 (+0.15%)
AAPL   236.24 (+0.01%)
FB   183.50 (-0.37%)
MSFT   139.89 (+0.15%)
GOOGL   1,220.67 (+0.41%)
AMZN   1,739.59 (+0.44%)
CGC   18.75 (-3.50%)
NVDA   186.48 (+0.26%)
MU   44.87 (-0.51%)
BABA   171.60 (-0.77%)
GE   8.74 (-0.68%)
TSLA   257.17 (+3.74%)
AMD   30.49 (+2.49%)
T   37.46 (-0.32%)
PRI   121.49 (-0.16%)
NFLX   286.50 (+1.26%)
BAC   29.06 (+0.52%)
GILD   64.48 (+0.75%)
DIS   129.77 (-0.19%)
Log in

AstraZeneca News Headlines (LON:AZN)

GBX 6,979
+63.00 (+0.91 %)
(As of 10/14/2019 03:06 PM ET)
Today's Range
6,903
Now: GBX 6,979
7,002
50-Day Range
6,793
MA: GBX 7,168.23
7,533
52-Week Range
5,312
Now: GBX 6,979
8,227.88
Volume1.61 million shs
Average Volume2.31 million shs
Market Capitalization£91.56 billion
P/E Ratio40.77
Dividend Yield3.17%
BetaN/A

Headlines

AstraZeneca (LON AZN) News Headlines

Source:
DateHeadline
AstraZeneca (LON:AZN) Given a GBX 7,900 Price Target at JPMorgan Chase & Co.AstraZeneca (LON:AZN) Given a GBX 7,900 Price Target at JPMorgan Chase & Co.
www.americanbankingnews.com - October 14 at 9:17 AM
AstraZeneca (LON:AZN) Earns "Overweight" Rating from BarclaysAstraZeneca (LON:AZN) Earns "Overweight" Rating from Barclays
www.americanbankingnews.com - October 9 at 6:39 AM
AstraZeneca HealthCare Foundation Awards $775000 to 11 Innovative Heart Health Programs & Announces Open Call for Applications - Business WireAstraZeneca HealthCare Foundation Awards $775000 to 11 Innovative Heart Health Programs & Announces Open Call for Applications - Business Wire
www.businesswire.com - October 8 at 1:09 PM
AstraZeneca (LON:AZN) Earns Buy Rating from Bank of AmericaAstraZeneca (LON:AZN) Earns Buy Rating from Bank of America
www.americanbankingnews.com - October 8 at 9:15 AM
AstraZeneca (LON:AZN) PT Set at GBX 7,900 by JPMorgan Chase & Co.AstraZeneca (LON:AZN) PT Set at GBX 7,900 by JPMorgan Chase & Co.
www.americanbankingnews.com - October 8 at 8:17 AM
AstraZenecas Fasenra Gets FDA Nod for Self-Administration - Yahoo FinanceAstraZeneca's Fasenra Gets FDA Nod for Self-Administration - Yahoo Finance
finance.yahoo.com - October 8 at 8:08 AM
AstraZeneca Launches Signature STEM Program to Empower Students to Live Healthier Lives and Inspire Future Scientists - Business WireAstraZeneca Launches Signature STEM Program to Empower Students to Live Healthier Lives and Inspire Future Scientists - Business Wire
www.businesswire.com - October 7 at 8:35 AM
AstraZeneca: FDA Approves Self-administration For Fasenra In Fasenra PenAstraZeneca: FDA Approves Self-administration For Fasenra In Fasenra Pen
www.nasdaq.com - October 6 at 7:54 AM
AstraZeneca (AZN) announces Fasenra approved in US for self-administration in new pre-filled auto-injector - StreetInsider.comAstraZeneca (AZN) announces Fasenra approved in US for self-administration in new pre-filled auto-injector - StreetInsider.com
www.streetinsider.com - October 5 at 1:22 AM
FDA approves AstraZeneca asthma drug for self-administration - Seeking AlphaFDA approves AstraZeneca asthma drug for self-administration - Seeking Alpha
seekingalpha.com - October 5 at 1:22 AM
FDA green lights AstraZeneca's asthma drug Fasenra for self-administrationFDA green lights AstraZeneca's asthma drug Fasenra for self-administration
finance.yahoo.com - October 4 at 3:19 AM
Viela Bio officially goes publicViela Bio officially goes public
finance.yahoo.com - October 3 at 5:13 PM
AstraZenecas Triple-Combo COPD Inhaler Gets CRL From FDA - Yahoo FinanceAstraZeneca's Triple-Combo COPD Inhaler Gets CRL From FDA - Yahoo Finance
finance.yahoo.com - October 2 at 4:05 PM
Why this UC Berkeley gene therapy spinout is targeting a $100 million IPOWhy this UC Berkeley gene therapy spinout is targeting a $100 million IPO
finance.yahoo.com - October 2 at 4:05 PM
Could the AstraZeneca share price continue to make new all-time highs?Could the AstraZeneca share price continue to make new all-time highs?
www.fool.co.uk - October 2 at 8:07 AM
FDA turns down AstraZenecas combo lung disease therapyFDA turns down AstraZeneca's combo lung disease therapy
seekingalpha.com - October 2 at 8:07 AM
Healthcare Companies Seek Innovative Ways to Combat New DiseasesHealthcare Companies Seek Innovative Ways to Combat New Diseases
www.bloomberg.com - October 2 at 8:07 AM
AstraZeneca Makes Great Prostate Cancer Treatment Showing, Targeting Specific Molecular Biomarker PatientsAstraZeneca Makes Great Prostate Cancer Treatment Showing, Targeting Specific Molecular Biomarker Patients
seekingalpha.com - October 2 at 8:07 AM
AstraZenecas combo lung disease therapy falls short of FDA approval - Yahoo FinanceAstraZeneca's combo lung disease therapy falls short of FDA approval - Yahoo Finance
finance.yahoo.com - October 1 at 10:06 PM
AstraZeneca (LON:AZN) Given a GBX 5,500 Price Target by Goldman Sachs Group AnalystsAstraZeneca (LON:AZN) Given a GBX 5,500 Price Target by Goldman Sachs Group Analysts
www.americanbankingnews.com - October 1 at 7:55 AM
HSBC Reaffirms "Reduce" Rating for AstraZeneca (LON:AZN)HSBC Reaffirms "Reduce" Rating for AstraZeneca (LON:AZN)
www.americanbankingnews.com - October 1 at 7:19 AM
Does AstraZenecas (LON:AZN) Share Price Gain of 66% Match Its Business Performance? - Yahoo FinanceDoes AstraZeneca's (LON:AZN) Share Price Gain of 66% Match Its Business Performance? - Yahoo Finance
finance.yahoo.com - October 1 at 7:18 AM
AstraZeneca sells acid reflux drug rights to Germanys Cheplapharm - ReutersAstraZeneca sells acid reflux drug rights to Germany's Cheplapharm - Reuters
www.reuters.com - October 1 at 7:18 AM
AstraZeneca sells acid reflux drug rights to Germany's CheplapharmAstraZeneca sells acid reflux drug rights to Germany's Cheplapharm
finance.yahoo.com - October 1 at 7:18 AM
Does AstraZeneca's (LON:AZN) Share Price Gain of 66% Match Its Business Performance?Does AstraZeneca's (LON:AZN) Share Price Gain of 66% Match Its Business Performance?
finance.yahoo.com - October 1 at 7:18 AM
Brexit stockpiling shows up in manufacturing data and bakery resultsBrexit stockpiling shows up in manufacturing data and bakery results
finance.yahoo.com - October 1 at 7:18 AM
AstraZeneca, Mercks Lynparza meets primary goal in late-stage study - Seeking AlphaAstraZeneca, Merck's Lynparza meets primary goal in late-stage study - Seeking Alpha
seekingalpha.com - October 1 at 2:18 AM
Could the AstraZeneca share price continue to make new all-time highs? - Yahoo Finance UKCould the AstraZeneca share price continue to make new all-time highs? - Yahoo Finance UK
uk.finance.yahoo.com - September 30 at 4:17 PM
Separate GSK, AstraZeneca trial results may widen ovarian cancer drug use - CNBCSeparate GSK, AstraZeneca trial results may widen ovarian cancer drug use - CNBC
www.cnbc.com - September 30 at 4:17 PM
AstraZeneca strengthens Lynparza push with prostate cancer dataAstraZeneca strengthens Lynparza push with prostate cancer data
finance.yahoo.com - September 30 at 4:17 PM
AstraZeneca (LON:AZN) Given Buy Rating at Deutsche BankAstraZeneca (LON:AZN) Given Buy Rating at Deutsche Bank
www.americanbankingnews.com - September 30 at 10:13 AM
AstraZeneca (LON:AZN) Earns Sell Rating from UBS GroupAstraZeneca (LON:AZN) Earns Sell Rating from UBS Group
www.americanbankingnews.com - September 30 at 10:13 AM
Jefferies Financial Group Reiterates GBX 6,550 Price Target for AstraZeneca (LON:AZN)Jefferies Financial Group Reiterates GBX 6,550 Price Target for AstraZeneca (LON:AZN)
www.americanbankingnews.com - September 30 at 10:03 AM
AstraZenecas (AZN) "Buy" Rating Reaffirmed at Shore CapitalAstraZeneca's (AZN) "Buy" Rating Reaffirmed at Shore Capital
www.americanbankingnews.com - September 30 at 7:22 AM
AstraZeneca, Merck cancer treatment attains meaningful improvement in progression-free survival - ReutersAstraZeneca, Merck cancer treatment attains meaningful improvement in progression-free survival - Reuters
www.reuters.com - September 30 at 2:54 AM
AstraZeneca, Merck cancer treatment attains meaningful improvement in progression-free survivalAstraZeneca, Merck cancer treatment attains meaningful improvement in progression-free survival
finance.yahoo.com - September 30 at 2:54 AM
AstraZeneca plc (LON:AZN) Given Average Recommendation of "Hold" by BrokeragesAstraZeneca plc (LON:AZN) Given Average Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - September 29 at 7:33 AM
Apple hires AstraZeneca execApple hires AstraZeneca exec
seekingalpha.com - September 27 at 9:14 PM
GSK, AstraZeneca rivalry takes center stage at cancer conference - Business InsiderGSK, AstraZeneca rivalry takes center stage at cancer conference - Business Insider
www.businessinsider.com - September 26 at 3:05 PM
Heres Why AstraZeneca (AZN) is Outperforming Its Industry - Yahoo FinanceHere's Why AstraZeneca (AZN) is Outperforming Its Industry - Yahoo Finance
finance.yahoo.com - September 26 at 3:05 PM
Zeneca Wilmington Inc. -- Moodys announces completion of a periodic review of ratings of AstraZeneca PLCZeneca Wilmington Inc. -- Moody's announces completion of a periodic review of ratings of AstraZeneca PLC
finance.yahoo.com - September 24 at 8:29 PM
AstraZeneca Gets CHMP Nod for Forxiga/Onglyza Combo Tablet - Yahoo FinanceAstraZeneca Gets CHMP Nod for Forxiga/Onglyza Combo Tablet - Yahoo Finance
finance.yahoo.com - September 24 at 3:29 PM
Bristol-Myers Squibb Company -- Moodys: Chinas rising demand for drugs will fuel foreign pharma companies growth into 2023Bristol-Myers Squibb Company -- Moody's: China's rising demand for drugs will fuel foreign pharma companies' growth into 2023
finance.yahoo.com - September 24 at 3:29 PM
AstraZenecas (AZN) "Hold" Rating Reiterated at Liberum CapitalAstraZeneca's (AZN) "Hold" Rating Reiterated at Liberum Capital
www.americanbankingnews.com - September 20 at 7:51 AM
AstraZeneca diabetes drug granted fast track status for heart failure treatment - ReutersAstraZeneca diabetes drug granted fast track status for heart failure treatment - Reuters
www.reuters.com - September 16 at 11:26 AM
AstraZenecas Latest Lung Cancer Test Data Makes It A Force To Be Reckoned With - Seeking AlphaAstraZeneca's Latest Lung Cancer Test Data Makes It A Force To Be Reckoned With - Seeking Alpha
seekingalpha.com - September 13 at 6:24 PM
Pharma Stock Roundup: Pipeline/Regulatory Updates From GSK, PFE & OthersPharma Stock Roundup: Pipeline/Regulatory Updates From GSK, PFE & Others
finance.yahoo.com - September 13 at 1:24 PM
AstraZeneca Sees 60% of China Sales From New Drugs in Five Years - BloombergAstraZeneca Sees 60% of China Sales From New Drugs in Five Years - Bloomberg
www.bloomberg.com - September 10 at 10:10 AM
AstraZenecas Executive VP Sees Upside, As Chinas Government Speeds Up New Drug Approval - Yahoo FinanceAstraZeneca's Executive VP Sees Upside, As China's Government Speeds Up New Drug Approval - Yahoo Finance
finance.yahoo.com - September 9 at 11:15 PM
AstraZeneca's Executive VP Sees Upside, As China's Government Speeds Up New Drug ApprovalAstraZeneca's Executive VP Sees Upside, As China's Government Speeds Up New Drug Approval
finance.yahoo.com - September 9 at 11:15 PM
This page was last updated on 10/14/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel